The state of the melatonin-associated hormonal system in children with overweight
Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Ball GDC, Savu A, Kaul P. Changes in the prevalence of overweight, obesity, and severe obesity between 2010 and 2017 in preschoolers: A population-based study. Pediatr Obes. 2019 Nov;14(11):e12561. doi: 10.1111/ijpo.12561.
Javed A, Jumean M, Murad MH, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity in children and adolescents: a systematic review and meta-analysis. Pediatr Obes. 2015 Jun;10(3):234-44. doi: 10.1111/ijpo.242.
Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011 Aug 27;378(9793):804-14. doi: 10.1016/S0140-6736(11)60813-1.
Psaltopoulou T, Tzanninis S, Ntanasis-Stathopoulos I, et al. Prevention and treatment of childhood and adolescent obesity: a systematic review of meta-analyses. World J Pediatr. 2019 Aug;15(4):350-381. doi: 10.1007/s12519-019-00266-y.
Trayhurn P. Adipocyte biology. Obes Rev. 2007 Mar;8 Suppl 1:41-4. doi: 10.1111/j.1467-789X.2007.00316.x.
Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56. doi: 10.1210/jc.2004-0395.
Aguilar-Valles A, Inoue W, Rummel C, Luheshi GN. Obesity, adipokines and neuroinflammation. Neuropharmacology. 2015 Sep;96(Pt A):124-34. doi: 10.1016/j.neuropharm.2014.12.023.
The American Association of Clinical Endocrinologists, American College of Endocrinology. 2014. Available from: https://www.aace.com/files/2014.
De Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem. 2008 Jun;54(6):945-55. doi: 10.1373/clinchem.2007.100156.
Leal Vde O, Mafra D. Adipokines in obesity. Clin Chim Acta. 2013 Apr 18;419:87-94. doi: 10.1016/j.cca.2013.02.003.
Ray I, Mahata SK, De RK. Obesity: An Immunometabolic Perspective. Front Endocrinol (Lausanne). 2016 Dec 12;7:157. doi: 10.3389/fendo.2016.00157.
Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond). 2006 Mar;30(3):400-18. doi: 10.1038/sj.ijo.0803177.
Gómez-Santos C, Gómez-Abellán P, Madrid JA, et al. Circadian rhythm of clock genes in human adipose explants. Obesity (Silver Spring). 2009 Aug;17(8):1481-5. doi: 10.1038/oby.2009.164.
Johnston JD. Adipose circadian rhythms: translating cellular and animal studies to human physiology. Mol Cell Endocrinol. 2012 Feb 5;349(1):45-50. doi: 10.1016/j.mce.2011.05.008.
Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda). 2014 Sep;29(5):325-33. doi: 10.1152/physiol.00011.2014.
Hardeland R, Madrid JA, Tan DX, Reiter RJ. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res. 2012 Mar;52(2):139-66. doi: 10.1111/j.1600-079X.2011.00934.x.
Bonnefont–Rousselot D. Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator. Endocr Metab Immune Disord Drug Targets. 2014;14(3):159-68. doi: 10.2174/1871530314666140604151452.
Cipolla-Neto J, Amaral FG, Afeche SC, Tan DX, Reiter RJ. Melatonin, energy metabolism, and obesity: a review. J Pineal Res. 2014 May;56(4):371-81. doi: 10.1111/jpi.12137.
Walecka-Kapica E, Chojnacki J, Stępień A, Wachowska-Kelly P, Klupińska G, Chojnacki C. Melatonin and female hormone secretion in postmenopausal overweight women. Int J Mol Sci. 2015 Jan 5;16(1):1030-42. doi: 10.3390/ijms16011030.
Bonnefont-Rousselot D. Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator. Endocr Metab Immune Disord Drug Targets. 2014;14(3):159-68. doi: 10.2174/1871530314666140604151452.
de Luxán-Delgado B, Caballero B, Potes Y, et al. Melatonin administration decreases adipogenesis in the liver of ob/ob mice through autophagy modulation. J Pineal Res. 2014 Mar;56(2):126-33. doi: 10.1111/jpi.12104.
Tanofsky-Kraff M, Yanovski SZ, Wilfley DE, Marmarosh C, Morgan CM, Yanovski JA. Eating-disordered behaviors, body fat, and psychopathology in overweight and normal-weight children. J Consult Clin Psychol. 2004 Feb;72(1):53-61. doi: 10.1037/0022-006X.72.1.53.
Mirzayi K, Hossein-Nejad A, Shamari M, Shahbazi S. Evidence of the role of ANGPTL6 in resting metabolic rate and its possible application in the treatment of obesity. Minerva Endocrinol. 2011 Mar;36(1):13-21.
Schoppen S, Riestra P, García-Anguita A, et al. Leptin and adiponectin levels in pubertal children: relationship with anthropometric variables and body composition. Clin Chem Lab Med. 2010 May;48(5):707-11. doi: 10.1515/CCLM.2010.142.
Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr. 2012 Jul 26;4(1):37. doi: 10.1186/1758-5996-4-37.
Wanders D, Plaisance EP, Judd RL. Lipid-lowering drugs and circulating adiponectin. Vitam Horm. 2012;90:341-74. doi: 10.1016/B978-0-12-398313-8.00013-0.
Halabis M, Dziedzic M, Warchulinska J, Kaznowska-Bystryk I, Solski J. Omentin – a new adipokine with many roles to play. Current Issues in Pharmacy and Medical Sciences. 2015 Sep;28(3): 176-180. doi: 10.1515/cipms-2015-0067.
Hossein-nezhad A, Mirzaei K, Alatab S, Ahmadivand Z, Najmafshar A. Circulating Omentin-1 in Obesity and Metabolic Syndrome Status Compared to Control Subjects. Endocrinol Metabol Syndrome. 2012;S1:008. doi:10.4172/2161-1017.S1-008.